Fermentalg successfully completed a €12.8 million capital increase designed to further its 2024-2026 strategic plan and consolidate its position as the European leader in sustainable solutions based on marine microalgae biotechnology. The HuvePharma group, European leader in precision fermentation in the animal and human health sectors, and a new industrial partner of Fermentalg since December 2023, invested €7.5 million, becoming a reference shareholder.

An expert in the research and bioindustrial exploitation of microalgae, Fermentalg aims to offer sustainable solutions and innovative products that contribute to the development of healthy, natural and high-performance products. It develops, produces and markets sustainable solutions and active ingredients derived from microalgae, for nutrition, health and the environment.

DegroofPetercam – IMAP France acted as financial adviser to Fermentalg, characterizing the company's financial needs, seeking potential financial and strategic partners, and structuring a market transaction with French banks for the execution of the Private Placement.